
Pfizer Inc. (NYSE:PFE) on Tuesday announced the initial results from a clinical trial called HER2CLIMB-05.
This trial tested a new treatment for patients with a type of breast cancer (metastatic breast cancer (MBC)) that is positive for HER2, which means the cancer cells have a specific protein that helps them grow.